(Total Views: 553)
Posted On: 02/25/2022 11:59:36 AM
Post# of 155776
you make a good point - an OTC biotech fits in the extremely risky realm.
The problem is that (and maybe it was just my problem) - i had perceived the company to have been somewhat "de-risked" by hitting the primary endpoints in the HIV trial. In other words, at the very least, we do a couple billion in revenue and trade at $10 billion market cap. Don't know if others had felt that way - but that lead me to invest more in this company than i would have otherwise.
The problem is that (and maybe it was just my problem) - i had perceived the company to have been somewhat "de-risked" by hitting the primary endpoints in the HIV trial. In other words, at the very least, we do a couple billion in revenue and trade at $10 billion market cap. Don't know if others had felt that way - but that lead me to invest more in this company than i would have otherwise.
(4)
(1)
